Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815929 · ClinicalTrials.gov registry record · Phase 2
Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT03815929: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03815929 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03815929, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Researchers are trying to assess the appropriate dose of estrogen for decreasing the risk of cardiovascular disease in women who have removal of their ovaries at a young age, before the age of 46 years.
Interventions
- DRUG Estradiol 100 Micrograms Patch
- DRUG Estradiol Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2023-08-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03815929
The ClinicalTrials.gov registry entry for NCT03815929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Estradiol 100 Micrograms Patch is the first listed.
NCT03815929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03815929 about?
NCT03815929 is a clinical study titled "Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women". Researchers are trying to assess the appropriate dose of estrogen for decreasing the risk of cardiovascular disease in women who have removal of their ovaries at a young age, before the age of 46 years.
What is the current status of trial NCT03815929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2019-03-15. Estimated completion is 2023-08-28.
What interventions are being tested in trial NCT03815929?
The interventions under investigation include: Estradiol 100 Micrograms Patch (DRUG), Estradiol Patch (DRUG).
Who is sponsoring clinical trial NCT03815929?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.